Insider Notice: CMA Proposes 2,100-Share Sale on NYSE Aug 8, 2025
Rhea-AI Filing Summary
Comerica Incorporated submitted a Form 144 reporting a proposed sale of 2,100 common shares through Fidelity Brokerage Services LLC with an aggregate market value of $140,773.50. The filing lists the approximate date of sale as 08/08/2025 and names the NYSE as the exchange, and reports total shares outstanding of 128,525,470.
The notice includes the acquisition history for the shares, showing multiple lots acquired between 03/31/2023 and 06/30/2025 via ESPP purchases and restricted stock vesting (notable vesting amounts include 854 and 524 shares). The provided content does not include the filer’s identifying CIK or filer name in the visible fields.
Positive
- None.
Negative
- None.
Insights
TL;DR: Proposed sale is disclosed and appears routine; the size reported is small relative to company capitalization.
The Form 144 specifies a planned sale of 2,100 common shares for $140,773.50 via Fidelity on the NYSE, with an approximate sale date of 08/08/2025. Acquisition records in the filing show the shares were obtained through periodic ESPP purchases and restricted stock vesting from 03/31/2023 through 06/30/2025. The filing reports no securities sold in the past three months. From a trading-disclosure perspective this is a routine insider notice and, based on the information presented, is not materially impactful to shareholders.
TL;DR: Filing shows compliant disclosure of planned insider sale; some filer identity fields are missing in the provided text.
The Form 144 includes broker details (Fidelity Brokerage Services LLC) and detailed acquisition lots (ESPP purchases and restricted vesting). The filing contains the required representation about absence of undisclosed material adverse information. However, the provided excerpt does not display the filer’s CIK or filer name in the visible sections, which are typically expected in the full filing record. Given the content shown, the filing reads as procedural and not governance-adverse.